The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK
Open accessAbstract
Constitutive overexpression and activation of NPM-ALK fusion protein [t(2:5)(p23;q35)] is a key oncogenic event that drives the survival and proliferation of anaplastic large-cell lymphomas (ALCLs). We have identified a highly potent and selective small-molecule ALK inhibitor, NVP-TAE684, which blocked the growth of ALCL-derived and ALK-dependent cell lines with IC 50 values between 2 and 10 nM. NVP-TAE684 treatment resulted in a rapid and sustained inhibition of phosphorylation of NPM-ALK and its downstream effectors and subsequent induction of apoptosis and cell cycle arrest. In vivo , NVP-TAE684 suppressed lymphomagenesis in two independent models of ALK-positive ALCL and induced regression of established Karpas-299 lymphomas. NVP-TAE684 also induced down-regulation of CD30 expression, suggesting that CD30 may be used as a biomarker of therapeutic NPM-ALK kinase activity inhibition.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fusion of a Kinase Gene, ALK , to a Nucleolar Protein Gene, NPM , in Non-Hodgkin's Lymphoma
Morris, S. W., Kirstein, M. N., Valentine, M. B., Dittmer, K. G., Shapiro, D. N., Saltman, D. L., & Look, A. T. (1994) · Science · doi:10.1126/science.8122112 · Cited by 2,409
Structural Mechanism for STI-571 Inhibition of Abelson Tyrosine Kinase
Schindler, T., Bornmann, W., Pellicena, P., Miller, W. T., Clarkson, B., & Kuriyan, J. (2000) · Science · doi:10.1126/science.289.5486.1938 · Cited by 1,780
Crystal structure of the tyrosine kinase domain of the human insulin receptor
Hubbard, S. R., Wei, L., & Hendrickson, W. A. (1994) · Nature · doi:10.1038/372746a0 · Cited by 1,080
Hubbard, S. R. (1997) · The EMBO Journal · doi:10.1093/emboj/16.18.5572 · Cited by 953
Structural Basis for the Autoinhibition and STI-571 Inhibition of c-Kit Tyrosine Kinase
Mol, C. D., Dougan, D. R., Schneider, T. R., Skene, R. J., Kraus, M. L., Scheibe, D. N., Snell, G. P., Zou, H., Sang, B.-C., & Wilson, K. P. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m403319200 · Cited by 635
Garcı́a-Echeverrı́a, C., Pearson, M. A., Marti, A., Meyer, T., Mestan, J., Zimmermann, J., Gao, J., Brueggen, J., Capraro, H.-G., Cozens, R., et al. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00051-0 · Cited by 542
Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target
Chiarle, R., Simmons, W. J., Cai, H., Dhall, G., Zamo, A., Raz, R., Karras, J. G., Levy, D. E., & Inghirami, G. (2005) · Nature Medicine · doi:10.1038/nm1249 · Cited by 442
Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death
Zamo, A., Chiarle, R., Piva, R., Howes, J., Fan, Y., Chilosi, M., Levy, D. E., & Inghirami, G. (2002) · Oncogene · doi:10.1038/sj.onc.1205152 · Cited by 399
Bai, R.-Y., Ouyang, T., Miething, C., Morris, S. W., Peschel, C., & Duyster, J. (2000) · Blood · doi:10.1182/blood.v96.13.4319 · Cited by 319
Gascoyne, R. D. (2003) · Blood · doi:10.1182/blood-2003-03-0786 · Cited by 297
Translocations involving anaplastic lymphoma kinase (ALK)
Duyster, J., Bai, R.-Y., & Morris, S. W. (2001) · Oncogene · doi:10.1038/sj.onc.1204594 · Cited by 279
NPM-ALK transgenic mice spontaneously develop T-cell lymphomas and plasma cell tumors
Chiarle, R., Gong, J. Z., Guasparri, I., Pesci, A., Cai, J., Liu, J., Simmons, W. J., Dhall, G., Howes, J., Piva, R., et al. (2003) · Blood · doi:10.1182/blood-2002-05-1343 · Cited by 252
Anaplastic lymphoma kinase proteins in growth control and cancer
Pulford, K., Morris, S. W., & Turturro, F. (2004) · Journal of Cellular Physiology · doi:10.1002/jcp.10472 · Cited by 227
An efficient rapid system for profiling the cellular activities of molecular libraries
Melnick, J. S., Janes, J., Kim, S., Chang, J. Y., Sipes, D. G., Gunderson, D., Jarnes, L., Matzen, J. T., Garcia, M. E., Hood, T. L., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0511292103 · Cited by 186
Self-citationAmin, H. M., McDonnell, T. J., Ma, Y., Lin, Q., Fujio, Y., Kunisada, K., Leventaki, V., Das, P., Rassidakis, G. Z., Cutler, C., et al. (2004) · Oncogene · doi:10.1038/sj.onc.1207703 · Cited by 173
Bonvini, P., Gastaldi, T., Falini, B., & Rosolen, A. (2002) · PubMed · Cited by 143
Amin, H. M., Medeiros, L. J., Ma, Y., Feretzaki, M., Das, P., Leventaki, V., Rassidakis, G. Z., O’Connor, S. L., McDonnell, T. J., & Lai, R. L. (2003) · Oncogene · doi:10.1038/sj.onc.1206849 · Cited by 142
Armstrong, F., Duplantier, M.-M., Trempat, P., Hiéblot, C., Lamant, L., Espinos, E., Racaud‐Sultan, C., Allouche, M., Campo, E., Delsol, G., et al. (2004) · Oncogene · doi:10.1038/sj.onc.1207813 · Cited by 129
Wan, W., Albom, M. S., Lü, L., Quail, M. R., Becknell, N. C., Weinberg, L. R., Reddy, D. R., Holskin, B. P., Angeles, T. S., Underiner, T. L., et al. (2005) · Blood · doi:10.1182/blood-2005-08-3254 · Cited by 111
Marzec, M., Kasprzycka, M., Liu, X., Raghunath, P. N., Wlodarski, P. K., & Wasik, M. A. (2006) · Oncogene · doi:10.1038/sj.onc.1209843 · Cited by 96
Bonvini, P., Rosa, H. D., Vignes, N., & Rosolen, A. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3531 · Cited by 92
Systemic and primary cutaneous anaplastic large cell lymphomas
Kadin, M. E., & Carpenter, C. F. (2003) · Seminars in Hematology · doi:10.1016/s0037-1963(03)00138-0 · Cited by 87
Marzec, M., Kasprzycka, M., Ptasznik, A., Wlodarski, P. K., Zhang, Q., Ødum, N., & Wasik, M. A. (2005) · Laboratory Investigation · doi:10.1038/labinvest.3700348 · Cited by 73
Molecular pathogenesis of chronic myeloid leukemia: implications for new therapeutic strategies
Warmuth, M., Danhauser-Riedl, S., & Hallek, M. J. (1999) · Annals of Hematology · doi:10.1007/s002770050473 · Cited by 68
Self-citationAnaplastic lymphoma kinase and its signalling molecules as novel targets in lymphoma therapy
Coluccia, A. M. L., Gunby, R. H., Tartari, C. J., Scapozza, L., Gambacorti-Passerini, C. B., & Passoni, L. (2005) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.9.3.515 · Cited by 24
Cited by
Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
Soda, M., Choi, Y. L., Enomoto, M., Takada, S., Yamashita, Y., Ishikawa, S., Fujiwara, S.-I., Watanabe, H., Kurashina, K., Hatanaka, H., et al. (2007) · Nature · doi:10.1038/nature05945 · Cited by 5,439
Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers
Katayama, R., Shaw, A. T., Khan, T. M., Mino-Kenudson, M., Solomon, B. J., Halmos, B., Jessop, N. A., Wain, J. C., Yeo, A. T., Benes, C., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003316 · Cited by 1,309
EML4-ALK Fusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung Cancer
Koivunen, J. P., Mermel, C., Zejnullahu, K., Murphy, C., Lifshits, E., Holmes, A. J., Choi, H. G., Kim, J., Chiang, D., Thomas, R., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0168 · Cited by 993
Self-citationSomatic and germline activating mutations of the ALK kinase receptor in neuroblastoma
Janoueix-Lerosey, I., Lequin, D., Brugières, L., Ribeiro, A., de Pontual, L., Combaret, V., Raynal, V., Puisieux, A., Schleiermacher, G., Pierron, G., et al. (2008) · Nature · doi:10.1038/nature07398 · Cited by 894
Activating mutations in ALK provide a therapeutic target in neuroblastoma
George, R. E., Sanda, T., Hanna, M., Fröhling, S., II, W. L., Zhang, J., Ahn, Y., Zhou, W., London, W. B., McGrady, P., et al. (2008) · Nature · doi:10.1038/nature07397 · Cited by 893
Self-citation
Metadata
- Authors
- Galkin, A. V., Melnick, J. S., Kim, S., Hood, T. L., Li, N., Li, L., Xia, G., Steensma, R., Chopiuk, G., Jiang, J., Wan, Y., Ding, P., Liu, Y., Sun, F., Schultz, P. G., Gray, N. S., & Warmuth, M.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2007-01-02
- Volume
- 104
- Issue
- 1
- Pages
- 270-275
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2014639631
- Cited by
- 379
- References
- 26
- FWCI
- 8.33
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.